↓ Skip to main content

Oral Human Abuse Potential of Oxycodone DETERx ® (Xtampza ® ER)

Overview of attention for article published in Journal of Clinical Pharmacology, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#24 of 1,607)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
4 news outlets
twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oral Human Abuse Potential of Oxycodone DETERx ® (Xtampza ® ER)
Published in
Journal of Clinical Pharmacology, November 2016
DOI 10.1002/jcph.833
Pubmed ID
Authors

Ernest A. Kopecky, Alison B. Fleming, Naama Levy-Cooperman, Melinda O'Connor, Edward M. Sellers

Abstract

Oxycodone DETERx(®) (Collegium Pharmaceutical Inc, Canton, MA) is an extended-release, microsphere-in-capsule, abuse-deterrent formulation designed to retain its extended-release properties after tampering (eg, chewing/crushing). This randomized, double-blind, placebo-controlled, triple-dummy study evaluated the oral abuse potential of intact and chewed oxycodone DETERx capsules compared with crushed immediate-release oxycodone. Subjects with a history of recreational opioid use who were nondependent/nontolerant to opioids were enrolled. Treatments included intact oxycodone DETERx (high-fat, high-calorie meal and fasted), chewed oxycodone DETERx (high-fat, high-calorie meal and fasted), crushed immediate-release oxycodone (fasted), and placebo (high-fat, high-calorie meal). Plasma samples were collected to determine pharmacokinetic parameters. The primary endpoint was drug liking at-the-moment; other endpoints included drug effects questionnaire scores, Addiction Research Center Inventory/Morphine Benzedrine Group score, pupillometry measurements, and safety. Thirty-eight subjects completed the study. Chewed and intact oxycodone DETERx were bioequivalent, unlike crushed immediate-release oxycodone, which yielded higher peak oxycodone plasma concentrations compared with all methods of oxycodone DETERx administration. The mean maximum (peak) effect (Emax ) for drug liking was significantly lower for chewed and intact oxycodone DETERx than for crushed immediate-release oxycodone (P<0.01). The time to Emax was significantly longer for chewed and intact oxycodone DETERx than for crushed immediate-release oxycodone (P<0.0001). Scores for feeling high and Addiction Research Center Inventory/Morphine Benzedrine Group scores demonstrated lower abuse potential for chewed and intact oxycodone DETERx compared with crushed immediate-release oxycodone. Study treatments were well tolerated; no subjects experienced serious adverse events. These results demonstrate lower oral abuse potential of chewed and intact oxycodone DETERx than crushed immediate-release oxycodone. This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Turkey 1 4%
Unknown 25 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 27%
Student > Doctoral Student 4 15%
Other 3 12%
Professor 2 8%
Student > Ph. D. Student 2 8%
Other 4 15%
Unknown 4 15%
Readers by discipline Count As %
Medicine and Dentistry 9 35%
Pharmacology, Toxicology and Pharmaceutical Science 7 27%
Nursing and Health Professions 3 12%
Neuroscience 1 4%
Engineering 1 4%
Other 0 0%
Unknown 5 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2017.
All research outputs
#413,249
of 12,454,625 outputs
Outputs from Journal of Clinical Pharmacology
#24
of 1,607 outputs
Outputs of similar age
#16,198
of 264,745 outputs
Outputs of similar age from Journal of Clinical Pharmacology
#5
of 36 outputs
Altmetric has tracked 12,454,625 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,607 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,745 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.